Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses some final opinions on immunotherapy agents in the landscape of head and neck cancer.
Tanguy Seiwert, MD
Advertisement
Articles by Tanguy Seiwert, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma
2
IDMC Recommends Continuation of Phase 2 MRD Study of IMNN-001 in Advanced Ovarian Cancer
3
Dr Mayer on the FDA Approval of Camizestrant for ESR1-Mutated Breast Cancer
4
INCB161734 Holds Potential Significance for KRAS G12D–Mutated mPDAC Management
5